We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 634.00 | 5.58% | 11,986.00 | 11,988.00 | 11,992.00 | 12,086.00 | 11,850.00 | 11,890.00 | 966,959 | 11:12:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.06 | 184.94B |
From Apr 2022 to Apr 2024
By Kyle Morris
AstraZeneca PLC said Tuesday that Eplontersen met co-primary and secondary endpoints in a phase 3 trial for hereditary transthyretin-mediated amyloid polyneuropathy.
The pharmaceutical company said that it got positive results from the trial and that eplontersen reached a statistically significant and clinically meaningful change from baseline for its co-primary endpoint of percent change in serum transthyretin concentration, reducing serum transthyretin protein production. Eplontersen also reached its co-primary endpoint of change from baseline in the modified Neuropathy Impairment Score +7 versus external placebo group.
Eplontersen will be jointly developed and commercialized with Ionis in the U.S. and developed and commercialized in the rest of the world by AstraZeneca.
The filing of a new drug application for eplontersen with the U.S. Food & Drug Administration is expected in 2022.
Hereditary transthyretin-mediated amyloid polyneuropathy is a disease that leads to nerve damage with motor disability within five years of diagnosis and, without treatment, can be fatal within 10 years.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
June 21, 2022 02:32 ET (06:32 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
